These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26902621)

  • 1. Indications for Augmentation Cystoplasty in the Era of OnabotulinumtoxinA.
    Shreck E; Gioia K; Lucioni A
    Curr Urol Rep; 2016 Apr; 17(4):27. PubMed ID: 26902621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
    Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
    Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?
    Koschorke M; Leitner L; Sadri H; Knüpfer SC; Mehnert U; Kessler TM
    BJU Int; 2017 Dec; 120(6):848-854. PubMed ID: 28771936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder.
    Ellsworth P; Travis M
    Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
    Cruz F; Nitti V
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost comparison of intra-detrusor injection of botulinum toxin versus augmentation cystoplasty for refractory neurogenic detrusor overactivity in children.
    Kim SJ; Nang QG; RoyChoudhury A; Kern AJM; Sheth K; Jacobs M; Poppas DP; Akhavan A
    J Pediatr Urol; 2022 Jun; 18(3):314-319. PubMed ID: 35216926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
    Gamé X; Khan S; Panicker JN; Kalsi V; Dalton C; Elneil S; Hamid R; Dasgupta P; Fowler CJ
    BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact.
    Nitti V; Haag-Molkenteller C; Kennelly M; Chancellor M; Jenkins B; Schurch B
    Medicine (Baltimore); 2023 Jul; 102(S1):e32377. PubMed ID: 37499088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Less is more-A pilot study evaluating one to three intradetrusor sites for injection of OnabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity.
    Avallone MA; Sack BS; El-Arabi A; Guralnick ML; O'Connor RC
    Neurourol Urodyn; 2017 Apr; 36(4):1104-1107. PubMed ID: 27283922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
    Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
    Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of onabotulinumtoxinA in patients with previous failed augmentation cystoplasty: Cohort series and literature review.
    Toia B; Pakzad MH; Hamid R; Wood DN; Greenwell TJ; Ockrim JL
    Neurourol Urodyn; 2020 Aug; 39(6):1831-1836. PubMed ID: 32572987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
    Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
    Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of botulinum toxin for genitourinary conditions: What is the evidence?
    da Silva CM; Chancellor MB; Smith CP; Cruz F
    Toxicon; 2015 Dec; 107(Pt A):141-7. PubMed ID: 26235907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.
    Carlson JJ; Hansen RN; Dmochowski RR; Globe DR; Colayco DC; Sullivan SD
    Clin Ther; 2013 Apr; 35(4):414-24. PubMed ID: 23522658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost comparison of intra-detrusor injection of botulinum toxin versus augmentation cystoplasty for refractory neurogenic detrusor overactivity in children.
    Kim SJ; Nang Q; RoyChoudhury A; Kern A; Sheth K; Jacobs M; Poppas D; Akhavan A
    J Pediatr Urol; 2022 Jun; 18(3):321-322. PubMed ID: 35305930
    [No Abstract]   [Full Text] [Related]  

  • 16. Higher Neural Correlates in Patients with Multiple Sclerosis and Neurogenic Overactive Bladder Following Treatment with Intradetrusor Injection of OnabotulinumtoxinA.
    Khavari R; Elias SN; Pande R; Wu KM; Boone TB; Karmonik C
    J Urol; 2019 Jan; 201(1):135-140. PubMed ID: 30076906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
    Nambiar A; Lucas M
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comment on: "Cost comparison of intra-detrusor injection of botulinum toxin versus augmentation cystoplasty for refractory Neurogenic Detrusor Overactivity in Children".
    Olsen LH; Djurhuus JC
    J Pediatr Urol; 2022 Jun; 18(3):323-324. PubMed ID: 35370093
    [No Abstract]   [Full Text] [Related]  

  • 19. Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity.
    Padmanabhan P; Scarpero HM; Milam DF; Dmochowski RR; Penson DF
    World J Urol; 2011 Feb; 29(1):51-7. PubMed ID: 21110030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intradetrusor botox injection and augmentation cystoplasty trends among spina bifida patients at US freestanding children's hospitals.
    Vasdev R; Softness K; Cahill D; Panagides J; Logvinenko T; Saunders R; Bauer S; Estrada C; Wang HS
    J Pediatr Urol; 2024 Jun; 20(3):482.e1-482.e6. PubMed ID: 38402080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.